We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+10.92%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$355M
AUM Growth
-$16.8M
Cap. Flow
-$17.7M
Cap. Flow %
-4.99%
Top 10 Hldgs %
50.26%
Holding
90
New
4
Increased
16
Reduced
25
Closed
11

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$9.25M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$4.36M
3
BHVN icon
Biohaven
BHVN
+$3.33M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.13M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.14M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$16.6M
2
CBAY
Cymabay Therapeutics
CBAY
+$5.82M
3
ACET icon
Adicet Bio
ACET
+$4.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$4.65M
5
ETNB
89bio
ETNB
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LCTX icon
76
Lineage Cell Therapeutics
LCTX
$277M
$164K 0.05%
140,000
– –
CGEN icon
77
Compugen
CGEN
$225M
$147K 0.04%
205,202
– –
REUN
78
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$42.9K 0.01%
47,679
-48,906
-51% -$71.3K
PHAS
79
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$9.69K ﹤0.01%
321,856
– –
CMPS
80
Compass Pathways
CMPS
$1.82B
– –
-47,390
Closed -$508K
GHRS icon
81
GH Research
GHRS
$2.03B
– –
-52,631
Closed -$612K
LITS
82
Lite Strategy Inc
LITS
$31.8M
– –
-88,357
Closed -$683K
PRQR icon
83
ProQR Therapeutics
PRQR
$265M
– –
-649,383
Closed -$483K
STRO icon
84
Sutro Biopharma
STRO
$422M
– –
-8,120
Closed -$451K
VERO
85
DELISTED
Venus Concept
VERO
– –
-5,868
Closed -$426K
NGM
86
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-74,953
Closed -$980K
GMDA
87
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-614,896
Closed -$978K
OTIC
88
DELISTED
Otonomy, Inc.
OTIC
– –
-1,470,199
Closed -$434K
AERI
89
DELISTED
Aerie Pharmaceuticals
AERI
– –
-307,232
Closed -$4.65M
BHVN
90
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-110,100
Closed -$16.6M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, DAFNA Capital Management held 90 positions worth $355M, down 4.5% from $372M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management withdrew a net $17.7M in Q4 2022, closing 11 positions and reducing 25 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $16.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 82% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in BioCryst Pharmaceuticals worth $2.88M.

  • DAFNA Capital Management's largest Q4 2022 buy was BioCryst Pharmaceuticals: 251,000 shares worth $2.88M.
  • DAFNA Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q4 2022, an estimated $9.25M increase.
  • DAFNA Capital Management's biggest Q4 2022 reduction was Cymabay Therapeutics, cutting an estimated $5.82M.
  • DAFNA Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $16.6M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $355M portfolio in Q4 2022.
  • DAFNA Capital Management opened 4 new positions and closed 11 in Q4 2022.
  • DAFNA Capital Management's portfolio value fell 4.5% quarter-over-quarter to $355M.

Based on DAFNA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.